Homology Medicines, Inc.

A securities class action has been filed against Homology Medicines, Inc.(FIXX) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 through February 18, 2022.  This case has been filed in the USDC – E.D.N.Y.

On February 18, 2022, Homology issued a press release disclosing that “the U.S. Food and Drug Administration has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests” and that “[t]he Company expects to receive an official clinical hold letter within 30 days.”

On this news, Homology’s stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022.